# Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

> **NCT00093028** · PHASE3 · COMPLETED · sponsor: **University of Arkansas** · enrollment: 315 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** CC-5013 (Revlimid™)
- **DRUG:** bortezomib

## Key facts

- **NCT ID:** NCT00093028
- **Lead sponsor:** University of Arkansas
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** 2006-01
- **Final completion:** 2006-01
- **Target enrollment:** 315 (ACTUAL)
- **Last updated:** 2010-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093028, "Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00093028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*